AbbVie: Bullish Institutional Buying To Send The Stock Higher
AbbVie's recent price appreciation on high volume appears to be institutional buying after positive data was released on both patent protection and its pipeline
abbv has gone up so much and so fast, leading me to wonder if I should cash it out to book the gain or continue to hold. It is much more expensive than it ever been, but then its value was held down because of the company's depedency on humira.
Look like Humira will be OK as the company forecasted. And its pipelines look good. If the pipelines have above average industry's success rate in winning FDA approval, the stock may still be cheap compares to MRK and other big pharma.
I'm glad I didn't sell this back months ago. it stalled at 70 for quite before the recent explosion! plus it pays dividends!
ABT & ABBV are two well run company's. Stockholders can give thanks to the brilliant leadership of Miles White. Hold on, for the next ride up! There's money to be made with a patient investment in ABBVIE.
Things seem to be getting overextended for ABBV. I started receiving notifications from https://hotstocks123.blogspot.com the other week and so far they have presented interesting new trade ideas.
there is something up. This is more than profit taking after a run up.
ACHN and GILD had their butts handed to them in the hep-c space by ABBV. Will continue to be one of ABBV's biggest winners for years to come.
Even after the biggest run up in its history this week, the stock still has over 3% yield and a pe of 20, much lower than mrk and other big pharma.
Tomorrow will be a pullback day. Incredible run, though!
Abbott used to split when the stock steadied at $70-$80, let's hope AbbVie follows suit!
Stocks require a but of patience and luck. I entered wrong, very wrong at 74 in July, I lowered at 72 and even at 70, but then had the feeling it was capped at 74-75, yet that forward PE looked so low. This big news now let it jump, yet the forward PE remain very low, with improved spirit, this stock might have room to go to above 100 without altering the PE at all ... curious to see how target price will adapt.
The pipeline and outlook for this company is really good. It's about time it catches up.
I guess we call this a "break out" ?
Since the ABT spinoff when it had an avg net value of $103 billion, ABBV is now worth $130 & ABT $89 billion. Almost $220 billion. Not bad and it allows workers who were fortunate enough to put in 30 years, to retire millionaires.
sold all 500 shares in my roth @ 89ish, holding from approx 54/share - and NO tax liability. will get back in if it goes to the 70's, or maybe if they do a 2 for 1 split. glta